Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Dosset, Magalie, Joseph, Elodie Lauret-Marie, Rivera Vargas, Thaiz, Apetoh, Lionel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408477/
https://www.ncbi.nlm.nih.gov/pubmed/32707692
http://dx.doi.org/10.3390/cells9071727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408477/
https://www.ncbi.nlm.nih.gov/pubmed/32707692
http://dx.doi.org/10.3390/cells9071727

Ejemplares similares